BCL2 and hematopoietic and lymphoid cell neoplasm: Based on Table 3, several unexpected treatment options emerged for medulloblastoma, including Venetoclax, a BCL2-targeted therapy commonly used in hematologic cancers but rarely applied to solid tumors [45].